Skip To Main Content
Coaquira Castro on Muck Rack

Coaquira Castro

As seen in: Frontiers in Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Coaquira Castro’s profile

Articles by Coaquira Castro

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons | Advances in Therapy

|
By Coaquira Castro, BeOne Medicines
| link.springer.com
Abstract Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of all esophageal cancer cases and is associated with poor prognosis. However, recent advancements have transformed the treatment landscape. Tislelizumab, a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody, was developed to overcome resistance mechanisms by minimizing binding to FcγR on macrophages.
Open in Who Shared Issue with article?

Frontiers | Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma

|
By Université de Poitiers, Hyun Ae, Coaquira Castro
| Frontiers in Immunology
SYSTEMATIC REVIEW article Front. Immunol. Sec.
Open in Who Shared Issue with article?
Show More